ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers
Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other
Subscription Journals (Source: Google Analytics)

Eulàlia Genesca

Dr.Eulàlia Genesca
Institut de Recerca Oncològica (IRO) in Barcelona
Department of Medical and Molecular Genetics

Postdoctoral Investigator Eulàlia completed her doctoral thesis at the Institut de Recerca Oncològica (IRO) in Barcelona at the Department of Medical and Molecular Genetics headed by Dr. Xavier Estivill. The experimental work was focused on elucidating the functional role of unknown genes that map in the human chromosome 21 (HC21). The group named it DSCR1 (Down Syndrome Candidate Region 1) and it was reported as an endogenous regulator of calcineurin phosphatase. As a postdoctoral researcher she joined the CRG in Barcelona, where she continued working on the DSCR1 protein elucidating the inhibition mechanism. Her experience in the ALL field began when she started a postdoctoral position in France, in the laboratory of Dr. Jacques Ghysdael at the Institut Curie in Orsay, Paris. There she investigated the pro-oncogenic function of the calcineurin/NFAT pathway in a mouse model of T-ALL induced by over expression of Notch 1 in pre-leukaemic cells. The leukaemic mouse model allowed the group to find evidence that calcineurin is key for the re-initiation of leukaemia in mice. After moving to the Institut Universitaire d'Hematologie in the laboratory of Prof. Jean Soulier, also in Paris, Eulàlia's research in ALL disease became more clinically oriented. She developed a xenograft mouse model of T-ALL and used it to functionally characterize two candidate tumour suppressor genes.Currently, she is in charge of the laboratory for the T-ALL research line at the Josep Carreras Leukemia Research Institute. Here her research is focused on the identification of copy number alterations as targets for available drugs involved in T-ALL leukemogenesis and prognosis.

Research Interest

identification of copy number alterations as targets for available drugs involved in T-ALL leukemogenesis and prognosis

Global Speakers in the subject

Global Experts in the subject

OMICS International Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
OMICS International Conferences 2016-17
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Materials Science Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version